首页 > 最新文献

Clinical Endocrinology最新文献

英文 中文
Trabecular bone score norms in Asian-Indians and associations with serum 25(OH)D and parathyroid hormone. 亚裔印度人的骨小梁评分标准以及与血清 25(OH)D 和甲状旁腺激素的关系。
IF 3 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-07 DOI: 10.1111/cen.15122
Velmurugan Mannar, Anand Vishal, Soma Saha, Mani Kalaivani, Devasenathipathy Kandasamy, Ravinder Goswami

Objective: There is limited information on population-specific norms of trabecular-bone-score (TBS) and its associated factors. Here, we provide norms of TBS in Asian-Indians and its relationship with serum 25-hydroxyvitamin D [25(OH)D] and intact-parathyroid hormone (iPTH).

Participants and measurements: TBS, bone-mineral-density (BMD), and vertebral-fractures (VFs) were assessed using dual-energy X-ray absorptiometry in 923 healthy Asian-Indians (aged 20-60 years). Serum 25(OH)D, iPTH, T4/TSH,, glycosylated-haemoglobin (HbA1c) were measured and associations with TBS assessed using multivariable linear regression. Subjects with BMD Z-score ≤ -2.0 or ≥2.0 at any sites, VFs, TSH > 10.0 or <0.05 µIU/ml, blood-glucose >11.1 mmol/L or HbA1c > 8.0% were excluded for generating Asian-Indian norms.

Results: TBS norms were generated in 744 healthy Asian-Indians (M:F,389:385). The cut-offs generated for 'normal', 'partially-degraded', and 'degraded' TBS were >1.305, 1.204-1.305 and <1.204, respectively. Mean TBS was lower in females than males (p < .001). There was 75% congruency in TBS categories between Asian-Indian and existing norms. Specificity (97.8 vs. 77.9%, p < .001) and diagnostic-accuracy (97.8% vs. 78.4%, p < .001) of TBS to detect osteoporosis were higher with Asian-Indian norms. The sensitivity of 'partially-degraded' TBS to diagnose osteopenia was also higher with Asian-Indian norms. In multivariable regression, gender, body-mass-index (BMI), BMD-L1-L4, serum PTH, daily dietary-calorie intake and calcium intake were associated with TBS. Though 25(OH)D inversely correlated with PTH, 25(OH)D was not associated with TBS.

Conclusion: This study provides norms for TBS in Asian-Indians with gender-specific differences. Increasing age and higher BMI were associated with lower TBS. Associations of TBS with circulating PTH and/or 25(OH)D need confirmation in further studies.

目的:关于特定人群的小梁-骨分数(TBS)标准及其相关因素的信息很有限。在此,我们提供了亚裔印度人的 TBS 标准及其与血清 25- 羟维生素 D [25(OH)D] 和完整甲状旁腺激素 (iPTH) 的关系:采用双能 X 射线吸收测量法对 923 名健康的亚裔印度人(20-60 岁)的 TBS、骨矿物质密度(BMD)和脊椎骨折(VFs)进行了评估。测量了血清 25(OH)D、iPTH、T4/TSH、糖化血红蛋白(HbA1c),并使用多变量线性回归评估了与 TBS 的关系。在生成亚印标准时,排除了任何部位的 BMD Z 评分≤-2.0 或≥2.0、VFs、TSH > 10.0 或 11.1 mmol/L 或 HbA1c > 8.0% 的受试者:在 744 名健康的亚裔印度人(男:女,389:385)中生成了 TBS 标准。正常"、"部分降解 "和 "降解 "TBS 的临界值分别为 >1.305、1.204-1.305 和 1-L4,血清 PTH、每日膳食卡路里摄入量和钙摄入量与 TBS 相关。虽然 25(OH)D 与 PTH 呈反比,但 25(OH)D 与 TBS 无关:本研究提供了亚裔印度人 TBS 的标准,其中存在性别差异。年龄越大、体重指数越高,TBS 越低。TBS与循环PTH和/或25(OH)D的关系需要进一步研究证实。
{"title":"Trabecular bone score norms in Asian-Indians and associations with serum 25(OH)D and parathyroid hormone.","authors":"Velmurugan Mannar, Anand Vishal, Soma Saha, Mani Kalaivani, Devasenathipathy Kandasamy, Ravinder Goswami","doi":"10.1111/cen.15122","DOIUrl":"https://doi.org/10.1111/cen.15122","url":null,"abstract":"<p><strong>Objective: </strong>There is limited information on population-specific norms of trabecular-bone-score (TBS) and its associated factors. Here, we provide norms of TBS in Asian-Indians and its relationship with serum 25-hydroxyvitamin D [25(OH)D] and intact-parathyroid hormone (iPTH).</p><p><strong>Participants and measurements: </strong>TBS, bone-mineral-density (BMD), and vertebral-fractures (VFs) were assessed using dual-energy X-ray absorptiometry in 923 healthy Asian-Indians (aged 20-60 years). Serum 25(OH)D, iPTH, T4/TSH,, glycosylated-haemoglobin (HbA1c) were measured and associations with TBS assessed using multivariable linear regression. Subjects with BMD Z-score ≤ -2.0 or ≥2.0 at any sites, VFs, TSH > 10.0 or <0.05 µIU/ml, blood-glucose >11.1 mmol/L or HbA1c > 8.0% were excluded for generating Asian-Indian norms.</p><p><strong>Results: </strong>TBS norms were generated in 744 healthy Asian-Indians (M:F,389:385). The cut-offs generated for 'normal', 'partially-degraded', and 'degraded' TBS were >1.305, 1.204-1.305 and <1.204, respectively. Mean TBS was lower in females than males (p < .001). There was 75% congruency in TBS categories between Asian-Indian and existing norms. Specificity (97.8 vs. 77.9%, p < .001) and diagnostic-accuracy (97.8% vs. 78.4%, p < .001) of TBS to detect osteoporosis were higher with Asian-Indian norms. The sensitivity of 'partially-degraded' TBS to diagnose osteopenia was also higher with Asian-Indian norms. In multivariable regression, gender, body-mass-index (BMI), BMD-L<sub>1</sub>-L<sub>4</sub>, serum PTH, daily dietary-calorie intake and calcium intake were associated with TBS. Though 25(OH)D inversely correlated with PTH, 25(OH)D was not associated with TBS.</p><p><strong>Conclusion: </strong>This study provides norms for TBS in Asian-Indians with gender-specific differences. Increasing age and higher BMI were associated with lower TBS. Associations of TBS with circulating PTH and/or 25(OH)D need confirmation in further studies.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141901136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pituitary deficiencies related to optic nerve hypoplasia and visual acuity. 与视神经发育不全和视敏度有关的垂体缺陷。
IF 3 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-08-04 DOI: 10.1111/cen.15125
Alison Murray, Terry Schwartz, Lindsey Hornung, Sarah Lawson

Objective: Optic nerve hypoplasia (ONH), the congenital underdevelopment of the optic nerve, is an increasing cause of visual impairment and is associated with pituitary dysfunction. Past studies have focused on the relationship between ONH, pituitary deficiencies, and brain imaging. However, recent studies have demonstrated the true risk for hypopituitarism lies with the presence or absence of ONH, irrespective of midline brain findings. This study reviewed the relationship between the health of the optic nerve (visual acuity) and pituitary gland (number and age of development of pituitary deficiencies) as a way to stratify risk, regardless of imaging findings.

Design, patients and measurements: Retrospective chart review of 197 patients seen at a single center from 2013 to 2022. Visual assessment was defined by distance acuity, and the presence of nystagmus or afferent pupillary defect. Pituitary deficiencies were diagnosed per Endocrine Society guidelines.

Results: In children with bilateral ONH (bONH), profound visual impairment was associated with more pituitary deficiencies between 0 and 15 years of age. The odds of having any pituitary deficiency were 4.9 times higher (95% confidence interval [95% CI]: 2.4-10.1) for patients with bONH versus unilateral ONH (uONH). Central hypothyroidism was the most common first presenting pituitary deficiency followed by growth hormone across all patients.

Conclusion: This study shows a significant association between severity of visual impairment and increased probability of pituitary deficiencies in children with bONH versus uONH. Children with ONH require urgent endocrine evaluation due to risk of pituitary deficiencies, but risk stratification may also be based on severity of visual impairment.

目的:视神经发育不全(ONH)是先天性视神经发育不全的一种表现,是造成视力障碍的一个日益严重的原因,与垂体功能障碍有关。过去的研究主要关注视神经发育不全、垂体功能缺陷和脑成像之间的关系。然而,最近的研究表明,垂体功能减退症的真正风险在于是否存在 ONH,而与大脑中线的检查结果无关。本研究回顾了视神经健康(视力敏锐度)与垂体(垂体功能缺失的数量和发病年龄)之间的关系,以此对风险进行分层,而与影像学检查结果无关:对2013年至2022年在一个中心就诊的197名患者进行回顾性病历审查。视力评估以远距离视力、眼球震颤或传入性瞳孔缺损为标准。根据内分泌学会指南诊断垂体缺陷:结果:在双侧ONH(bONH)患儿中,0至15岁期间,深度视力损伤与更多垂体缺陷有关。与单侧视网膜缺损(uONH)患者相比,双侧视网膜缺损患者出现任何垂体缺陷的几率要高出4.9倍(95%置信区间[95% CI]:2.4-10.1)。在所有患者中,中枢性甲状腺功能减退症是最常见的首发垂体功能缺陷,其次是生长激素:本研究表明,在双侧视网膜缺损(bONH)与单侧视网膜缺损(uONH)患儿中,视力损伤的严重程度与垂体功能缺失的概率增加之间存在明显关联。由于垂体功能缺陷的风险,ONH患儿需要进行紧急内分泌评估,但也可根据视力障碍的严重程度进行风险分层。
{"title":"Pituitary deficiencies related to optic nerve hypoplasia and visual acuity.","authors":"Alison Murray, Terry Schwartz, Lindsey Hornung, Sarah Lawson","doi":"10.1111/cen.15125","DOIUrl":"10.1111/cen.15125","url":null,"abstract":"<p><strong>Objective: </strong>Optic nerve hypoplasia (ONH), the congenital underdevelopment of the optic nerve, is an increasing cause of visual impairment and is associated with pituitary dysfunction. Past studies have focused on the relationship between ONH, pituitary deficiencies, and brain imaging. However, recent studies have demonstrated the true risk for hypopituitarism lies with the presence or absence of ONH, irrespective of midline brain findings. This study reviewed the relationship between the health of the optic nerve (visual acuity) and pituitary gland (number and age of development of pituitary deficiencies) as a way to stratify risk, regardless of imaging findings.</p><p><strong>Design, patients and measurements: </strong>Retrospective chart review of 197 patients seen at a single center from 2013 to 2022. Visual assessment was defined by distance acuity, and the presence of nystagmus or afferent pupillary defect. Pituitary deficiencies were diagnosed per Endocrine Society guidelines.</p><p><strong>Results: </strong>In children with bilateral ONH (bONH), profound visual impairment was associated with more pituitary deficiencies between 0 and 15 years of age. The odds of having any pituitary deficiency were 4.9 times higher (95% confidence interval [95% CI]: 2.4-10.1) for patients with bONH versus unilateral ONH (uONH). Central hypothyroidism was the most common first presenting pituitary deficiency followed by growth hormone across all patients.</p><p><strong>Conclusion: </strong>This study shows a significant association between severity of visual impairment and increased probability of pituitary deficiencies in children with bONH versus uONH. Children with ONH require urgent endocrine evaluation due to risk of pituitary deficiencies, but risk stratification may also be based on severity of visual impairment.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Paediatric thyroid disease 小儿甲状腺疾病
IF 3 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-29 DOI: 10.1111/cen.15110
Timothy Cheetham, Claire Wood

The spectrum of thyroid disorders presenting to paediatricians is different to that seen by adult physicians. Referrals reflect cases detected by the neonatal screening programme for congenital hypothyroidism and many of the inherited defects of thyroid hormone generation or action will be manifest in early life. Autoimmune thyroid disease can be particularly challenging to manage in the young and the potential impact of thyroid status on neurodevelopment and schooling are key considerations throughout childhood and adolescence.

儿科医生接诊的甲状腺疾病患者与成人医生不同。转诊病例反映的是新生儿先天性甲状腺功能减退症筛查项目中发现的病例,许多遗传性甲状腺激素生成或作用缺陷都会在生命早期表现出来。自身免疫性甲状腺疾病对青少年的治疗尤其具有挑战性,而甲状腺状态对神经发育和学业的潜在影响是整个儿童和青少年时期的主要考虑因素。
{"title":"Paediatric thyroid disease","authors":"Timothy Cheetham,&nbsp;Claire Wood","doi":"10.1111/cen.15110","DOIUrl":"10.1111/cen.15110","url":null,"abstract":"<p>The spectrum of thyroid disorders presenting to paediatricians is different to that seen by adult physicians. Referrals reflect cases detected by the neonatal screening programme for congenital hypothyroidism and many of the inherited defects of thyroid hormone generation or action will be manifest in early life. Autoimmune thyroid disease can be particularly challenging to manage in the young and the potential impact of thyroid status on neurodevelopment and schooling are key considerations throughout childhood and adolescence.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cen.15110","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucose metabolism and radiodensity of abdominal adipose tissue: A 5-year longitudinal study in a large PET cohort. 葡萄糖代谢与腹部脂肪组织的放射密度:一项为期 5 年的大型 PET 队列纵向研究。
IF 3 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-22 DOI: 10.1111/cen.15121
Kyoungjune Pak, Severi Santavirta, Seunghyeon Shin, Hyun-Yeol Nam, Sven De Maeyer, Lauri Nummenmaa

Objective: 18F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) allows noninvasive assessment of glucose metabolism and radiodensity in visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). We aimed to address the effects of ageing and metabolic factors on abdominal adipose tissue.

Design, patients and measurements: We retrospectively analyzed data from 435 healthy men (mean 42.8 years) who underwent a health check-up programme twice, at baseline and the 5-year follow-up. The mean standardized uptake value (SUV) was measured using SAT and VAT and divided by the liver SUV. The mean Hounsfield units (HU) of the SAT and VAT were measured from the CT scans. The effects of clinical variable clusters on SUVR were investigated using Bayesian hierarchical modelling; metabolic cluster (BMI, waist-to-hip ratio, fat percentage, muscle percentage*-1, HOMA-IR), blood pressure (systolic, diastolic), glucose (fasting plasma glucose level, HbA1c) and C-reactive protein.

Results: All the clinical variables changed during the 5-year follow-up period. The SUVR and HU of the VAT increased during follow-up; however, those of the SAT did not change. SUVR and HU were positively correlated with both VAT and SAT. SAT and VAT SUVR were negatively associated with metabolic clusters.

Conclusions: Ageing led to increased glucose metabolism and radiodensity in VAT, but not in SAT. VAT may reflect the ageing process more directly than SAT. Glucose metabolism was higher and radiodensity was lower in VAT than in SAT, probably owing to differences in gene expression and lipid density. Both glucose metabolism and radiodensity of VAT and SAT reflect metabolic status.

目的:18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描(PET/CT)可对内脏脂肪组织(VAT)和皮下脂肪组织(SAT)的葡萄糖代谢和放射密度进行无创评估。我们的目的是研究衰老和代谢因素对腹部脂肪组织的影响:我们对 435 名健康男性(平均 42.8 岁)的数据进行了回顾性分析,他们分别在基线和 5 年随访期间接受了两次健康检查。使用 SAT 和 VAT 测量平均标准化摄取值 (SUV),然后除以肝脏 SUV。SAT 和 VAT 的平均 Hounsfield 单位 (HU) 是通过 CT 扫描测得的。使用贝叶斯层次模型研究了临床变量组群对 SUVR 的影响;代谢组群(体重指数、腰臀比、脂肪百分比、肌肉百分比*-1、HOMA-IR)、血压(收缩压、舒张压)、血糖(空腹血浆葡萄糖水平、HbA1c)和 C 反应蛋白:所有临床变量在 5 年随访期间都发生了变化。VAT的SUVR和HU在随访期间有所增加,但SAT的SUVR和HU没有变化。SUVR和HU与VAT和SAT均呈正相关。SAT和VAT的SUVR与代谢群呈负相关:结论:老龄化导致 VAT 的糖代谢和放射密度增加,但 SAT 却没有。VAT可能比SAT更能直接反映衰老过程。与 SAT 相比,VAT 的葡萄糖代谢率更高,放射性密度更低,这可能是由于基因表达和脂质密度的差异。VAT 和 SAT 的葡萄糖代谢和辐射密度都反映了代谢状况。
{"title":"Glucose metabolism and radiodensity of abdominal adipose tissue: A 5-year longitudinal study in a large PET cohort.","authors":"Kyoungjune Pak, Severi Santavirta, Seunghyeon Shin, Hyun-Yeol Nam, Sven De Maeyer, Lauri Nummenmaa","doi":"10.1111/cen.15121","DOIUrl":"https://doi.org/10.1111/cen.15121","url":null,"abstract":"<p><strong>Objective: </strong><sup>18</sup>F-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) allows noninvasive assessment of glucose metabolism and radiodensity in visceral adipose tissue (VAT) and subcutaneous adipose tissue (SAT). We aimed to address the effects of ageing and metabolic factors on abdominal adipose tissue.</p><p><strong>Design, patients and measurements: </strong>We retrospectively analyzed data from 435 healthy men (mean 42.8 years) who underwent a health check-up programme twice, at baseline and the 5-year follow-up. The mean standardized uptake value (SUV) was measured using SAT and VAT and divided by the liver SUV. The mean Hounsfield units (HU) of the SAT and VAT were measured from the CT scans. The effects of clinical variable clusters on SUVR were investigated using Bayesian hierarchical modelling; metabolic cluster (BMI, waist-to-hip ratio, fat percentage, muscle percentage*-1, HOMA-IR), blood pressure (systolic, diastolic), glucose (fasting plasma glucose level, HbA1c) and C-reactive protein.</p><p><strong>Results: </strong>All the clinical variables changed during the 5-year follow-up period. The SUVR and HU of the VAT increased during follow-up; however, those of the SAT did not change. SUVR and HU were positively correlated with both VAT and SAT. SAT and VAT SUVR were negatively associated with metabolic clusters.</p><p><strong>Conclusions: </strong>Ageing led to increased glucose metabolism and radiodensity in VAT, but not in SAT. VAT may reflect the ageing process more directly than SAT. Glucose metabolism was higher and radiodensity was lower in VAT than in SAT, probably owing to differences in gene expression and lipid density. Both glucose metabolism and radiodensity of VAT and SAT reflect metabolic status.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tracking dynamic evolution of low- and intermediate-risk differentiated thyroid cancer: Identification of individuals at risk of recurrence 跟踪低危和中危分化型甲状腺癌的动态演变:识别有复发风险的个体
IF 3 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-22 DOI: 10.1111/cen.15111
Federico Volpi, Juan Alcalde, Javier Larrache, Estíbaliz Alegre, Allan Argueta, María D. Lozano, Carla Colombo, Juan C. Galofré

Objective

The generally good prognosis of low- and intermediate-risk differentiated thyroid cancer (DTC) underscored the need to identify those few patients who relapse.

Design

Records of 299 low- or intermediate-risk DTC patients (mean follow-up 8.2 ± 6.2 years) were retrospectively reviewed. The sample was classified following the American Thyroid Association (ATA) dynamic risk stratification (DRS) system.

Patients and Measurement

After classifying patients according to DRS at the first visit following initial therapy (FU1), structural recurrence occurred in 2/181 (1.1%), 5/81 (6.2%) and 13/26 (50.0%) with excellent, indeterminate and biochemical incomplete response to treatment, respectively. All relapses but one happened within 5 years from FU1. Univariate analysis comparing excellent, indeterminate and biochemical incomplete with structural incomplete responses at the end of the follow-up, identified tumour size (p < .001), T status (<0.001), positive lymph nodes (N) (p < .01), multifocality (p < .004), need of additional radioactive iodine (RAI) (p < .0001) and first DRS status (p < .0003) as risk factors of recurrence. In the multivariate analysis, only RAI remained statistically significant (p < .02). Comparison between excellent and indeterminate with biochemical and structural incomplete responses, identified tumour size (p < .0004), T (p < .01), N (p < .0001), bilaterality (p < .03), first DRS status (p < .0001) and RAI (p < .001) as recurrence risk factors. T (p < .01) and first DRS (p < .0006) were confirmed in the multivariate analysis.

Conclusions

Patients with DTC classified as low- or intermediate-risk of recurrence with excellent response to treatment at FU1 rarely develop structural disease and this occurs almost exclusively in the first 5 years. Initial DRS status is an accurate tool for determining the risk of recurrence.

目的低危和中危分化型甲状腺癌(DTC)的预后普遍较好,因此有必要找出少数复发患者:设计:回顾性研究了299例低危或中危DTC患者的病历(平均随访时间为8.2 ± 6.2年)。样本按照美国甲状腺协会(ATA)动态风险分层(DRS)系统进行分类:在初始治疗后首次就诊(FU1)时根据 DRS 对患者进行分类后,结构性复发分别发生在 2/181(1.1%)、5/81(6.2%)和 13/26(50.0%)例患者中,这些患者对治疗的反应分别为良好、不确定和生化反应不完全。除一次复发外,所有复发均发生在自FU1起的5年内。单变量分析比较了随访结束时的极佳反应、不确定反应、生化不完全反应和结构不完全反应,确定了肿瘤大小(P 结论:肿瘤大小越小,治疗效果越好:被归类为低危或中危复发的 DTC 患者在 FU1 时对治疗反应良好,但很少出现结构性疾病,而且这种情况几乎只发生在前 5 年。初始 DRS 状态是确定复发风险的准确工具。
{"title":"Tracking dynamic evolution of low- and intermediate-risk differentiated thyroid cancer: Identification of individuals at risk of recurrence","authors":"Federico Volpi,&nbsp;Juan Alcalde,&nbsp;Javier Larrache,&nbsp;Estíbaliz Alegre,&nbsp;Allan Argueta,&nbsp;María D. Lozano,&nbsp;Carla Colombo,&nbsp;Juan C. Galofré","doi":"10.1111/cen.15111","DOIUrl":"10.1111/cen.15111","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The generally good prognosis of low- and intermediate-risk differentiated thyroid cancer (DTC) underscored the need to identify those few patients who relapse.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design</h3>\u0000 \u0000 <p>Records of 299 low- or intermediate-risk DTC patients (mean follow-up 8.2 ± 6.2 years) were retrospectively reviewed. The sample was classified following the American Thyroid Association (ATA) dynamic risk stratification (DRS) system.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Patients and Measurement</h3>\u0000 \u0000 <p>After classifying patients according to DRS at the first visit following initial therapy (FU1), structural recurrence occurred in 2/181 (1.1%), 5/81 (6.2%) and 13/26 (50.0%) with excellent, indeterminate and biochemical incomplete response to treatment, respectively. All relapses but one happened within 5 years from FU1. Univariate analysis comparing excellent, indeterminate and biochemical incomplete with structural incomplete responses at the end of the follow-up, identified tumour size (<i>p</i> &lt; .001), <i>T</i> status (&lt;0.001), positive lymph nodes (<i>N</i>) (<i>p</i> &lt; .01), multifocality (<i>p</i> &lt; .004), need of additional radioactive iodine (RAI) (<i>p</i> &lt; .0001) and first DRS status (<i>p</i> &lt; .0003) as risk factors of recurrence. In the multivariate analysis, only RAI remained statistically significant (<i>p</i> &lt; .02). Comparison between excellent and indeterminate with biochemical and structural incomplete responses, identified tumour size (<i>p</i> &lt; .0004), <i>T</i> (<i>p</i> &lt; .01), <i>N</i> (<i>p</i> &lt; .0001), bilaterality (<i>p</i> &lt; .03), first DRS status (<i>p</i> &lt; .0001) and RAI (<i>p</i> &lt; .001) as recurrence risk factors. <i>T</i> (<i>p</i> &lt; .01) and first DRS (<i>p</i> &lt; .0006) were confirmed in the multivariate analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Patients with DTC classified as low- or intermediate-risk of recurrence with excellent response to treatment at FU1 rarely develop structural disease and this occurs almost exclusively in the first 5 years. Initial DRS status is an accurate tool for determining the risk of recurrence.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cen.15111","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747590","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Higher risk of incident diabetes among patients with primary hyperparathyroidism. 原发性甲状旁腺功能亢进症患者罹患糖尿病的风险更高。
IF 3 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-22 DOI: 10.1111/cen.15118
Yingchai Zhang, Hongjiang Wu, Aimin Yang, Noel Y H Ng, Xinge Zhang, Eric S H Lau, Edith W K Chow, Alice P S Kong, Elaine Y K Chow, Juliana C N Chan, Andrea O Y Luk, Ronald C W Ma

Objectives: There is relatively scarce data regarding the association between primary hyperparathyroidism (PHPT) and incident diabetes in large population-based longitudinal studies. We aimed to evaluate the risk of incident diabetes in individuals with and without PHPT and investigate the association between serum calcium concentrations and the risk of incident diabetes in patients with PHPT.

Methods: We included 2749 PHPT patients and 13,745 age, sex and index year matched non-PHPT individuals during 2000-2019. We used Cox regression models to compare the risk of incident diabetes in individuals with and without PHPT, and the risk of incident diabetes in PHPT patients with serum calcium concentration above and below the median value. The association between serum calcium concentrations and the risk of incident diabetes was examined by restricted cubic spline analyses in patients with PHPT.

Results: During a median follow-up time of 5.17 years (IQR 2.17, 9.58), 433 patients (15.75%) with PHPT and 2110 individuals (15.35%) without PHPT developed diabetes, respectively. Patients with PHPT had a higher incidence rate of diabetes compared to non-PHPT individuals (27.60 [95% CI 25.00, 30.30] vs. 23.90 [95% CI 22.80, 24.90] per 1000 person-years, log-rank test p = .007]. Crude Cox regression model showed PHPT was associated with a 15% higher risk of incident diabetes (HR 1.15, 95%CI 1.04, 1.28). In patients with PHPT, a 44% higher risk of incident diabetes was found in patients with serum calcium concentrations above the median value (2.63 mmol/L), compared to those below the median value (HR 1.44, 95%CI 1.08, 1.90). Restricted cubic spline analyses confirmed a positive linear association between serum calcium concentrations and the risk of incident diabetes in those with PHPT (p-value for nonlinear = .751) CONCLUSIONS: Patients with PHPT had a higher risk of incident diabetes compared to non-PHPT individuals. A positive linear association was found between serum calcium concentrations and the risk of incident diabetes in patients with PHPT.

研究目的在大型人群纵向研究中,有关原发性甲状旁腺功能亢进症(PHPT)与糖尿病发病之间关系的数据相对较少。我们旨在评估原发性甲状旁腺功能亢进症患者和非原发性甲状旁腺功能亢进症患者罹患糖尿病的风险,并调查血清钙浓度与原发性甲状旁腺功能亢进症患者罹患糖尿病风险之间的关系:我们纳入了 2000-2019 年间的 2749 名 PHPT 患者和 13745 名年龄、性别和指数年相匹配的非 PHPT 患者。我们使用Cox回归模型比较了PHPT患者和非PHPT患者的糖尿病发病风险,以及血清钙浓度高于和低于中位值的PHPT患者的糖尿病发病风险。通过对PHPT患者进行限制性三次样条分析,研究了血清钙浓度与糖尿病发病风险之间的关系:在中位 5.17 年(IQR 2.17,9.58)的随访时间内,分别有 433 名 PHPT 患者(15.75%)和 2110 名非 PHPT 患者(15.35%)罹患糖尿病。与非PHPT患者相比,PHPT患者的糖尿病发病率更高(27.60 [95% CI 25.00, 30.30] vs. 23.90 [95% CI 22.80, 24.90] per 1000 person-years,log-rank检验 p = .007)。粗略的考克斯回归模型显示,PHPT 与糖尿病发病风险增加 15% 相关(HR 1.15,95%CI 1.04,1.28)。在 PHPT 患者中,血清钙浓度高于中位值(2.63 mmol/L)的患者与低于中位值的患者相比,发生糖尿病的风险高出 44%(HR 1.44,95%CI 1.08,1.90)。限制性三次样条分析证实,PHPT 患者的血清钙浓度与糖尿病发病风险呈正线性关系(非线性的 p 值 = .751):与非PHPT患者相比,PHPT患者罹患糖尿病的风险更高。研究发现,PHPT 患者的血清钙浓度与糖尿病发病风险呈正线性关系。
{"title":"Higher risk of incident diabetes among patients with primary hyperparathyroidism.","authors":"Yingchai Zhang, Hongjiang Wu, Aimin Yang, Noel Y H Ng, Xinge Zhang, Eric S H Lau, Edith W K Chow, Alice P S Kong, Elaine Y K Chow, Juliana C N Chan, Andrea O Y Luk, Ronald C W Ma","doi":"10.1111/cen.15118","DOIUrl":"https://doi.org/10.1111/cen.15118","url":null,"abstract":"<p><strong>Objectives: </strong>There is relatively scarce data regarding the association between primary hyperparathyroidism (PHPT) and incident diabetes in large population-based longitudinal studies. We aimed to evaluate the risk of incident diabetes in individuals with and without PHPT and investigate the association between serum calcium concentrations and the risk of incident diabetes in patients with PHPT.</p><p><strong>Methods: </strong>We included 2749 PHPT patients and 13,745 age, sex and index year matched non-PHPT individuals during 2000-2019. We used Cox regression models to compare the risk of incident diabetes in individuals with and without PHPT, and the risk of incident diabetes in PHPT patients with serum calcium concentration above and below the median value. The association between serum calcium concentrations and the risk of incident diabetes was examined by restricted cubic spline analyses in patients with PHPT.</p><p><strong>Results: </strong>During a median follow-up time of 5.17 years (IQR 2.17, 9.58), 433 patients (15.75%) with PHPT and 2110 individuals (15.35%) without PHPT developed diabetes, respectively. Patients with PHPT had a higher incidence rate of diabetes compared to non-PHPT individuals (27.60 [95% CI 25.00, 30.30] vs. 23.90 [95% CI 22.80, 24.90] per 1000 person-years, log-rank test p = .007]. Crude Cox regression model showed PHPT was associated with a 15% higher risk of incident diabetes (HR 1.15, 95%CI 1.04, 1.28). In patients with PHPT, a 44% higher risk of incident diabetes was found in patients with serum calcium concentrations above the median value (2.63 mmol/L), compared to those below the median value (HR 1.44, 95%CI 1.08, 1.90). Restricted cubic spline analyses confirmed a positive linear association between serum calcium concentrations and the risk of incident diabetes in those with PHPT (p-value for nonlinear = .751) CONCLUSIONS: Patients with PHPT had a higher risk of incident diabetes compared to non-PHPT individuals. A positive linear association was found between serum calcium concentrations and the risk of incident diabetes in patients with PHPT.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141747589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gonadotropin treatment of cryptorchidism in congenital hypogonadotropic hypogonadism—Age is no limit? 促性腺激素治疗先天性低促性腺激素性性腺功能减退症的隐睾症--年龄没有限制?
IF 3 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-18 DOI: 10.1111/cen.15117
Neomal De Silva, Sasha R. Howard, Jacquelin O'Sullivan, Julia Russell, Annette Lee, Louise Duffy, Timothy Cheetham, Yaasir Mamoojee, Richard Quinton
{"title":"Gonadotropin treatment of cryptorchidism in congenital hypogonadotropic hypogonadism—Age is no limit?","authors":"Neomal De Silva,&nbsp;Sasha R. Howard,&nbsp;Jacquelin O'Sullivan,&nbsp;Julia Russell,&nbsp;Annette Lee,&nbsp;Louise Duffy,&nbsp;Timothy Cheetham,&nbsp;Yaasir Mamoojee,&nbsp;Richard Quinton","doi":"10.1111/cen.15117","DOIUrl":"10.1111/cen.15117","url":null,"abstract":"","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141632844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time to first remission and survival in patients with acromegaly: Evidence from the UK Acromegaly Register Study (UKAR) 肢端肥大症患者的首次缓解时间和存活率:来自英国渐冻人症登记研究(UKAR)的证据。
IF 3 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-16 DOI: 10.1111/cen.15112
Harshal Deshmukh, Emmanuel Ssemmondo, Kazeem Adeleke, Shiva Mongolu, Mo Aye, Steve Orme, Daniel Flanagan, Prakash Abraham, Claire Higham, Thozhukat Sathyapalan, UK Acromegaly Register Study (UKAR) Group

Objective

This study aimed to understand the effect of time to remission of acromegaly on survival in people living with acromegaly.

Design, Patients and Measurement

This cross-sectional study used data from the UK Acromegaly Register. We considered remission of acromegaly growth hormone controlled at ≤2 μg/L following the diagnosis of acromegaly. We used the accelerated failure time model to assess the effect of time to remission on survival in acromegaly.

Results

The study population comprises 3569 individuals with acromegaly, with a median age of diagnosis of 47.3 (36.5–57.8) years, 48% females and a majority white population (61%). The number of individuals with the first remission of acromegaly was 2472, and the median time to first remission was 1.92 (0.70–6.58) years. In this study, time to first remission in acromegaly was found to have a significant effect on survival (p < .001); for every 1-year increase in time to first remission, there was a median 1% reduction in survival in acromegaly. In an analysis adjusted for covariates, the survival rate was 52% higher (p < .001) in those who underwent surgery as compared to those who did not have surgery, 18% higher (p = .01) in those who received treatment with somatostatin analogues (SMA) as compared to those with dopamine agonists and 21% lower (p < .001) in those who received conventional radiotherapy as compared to those who did not receive radiotherapy.

Conclusion

In conclusion, this population-based study conducted in patients with acromegaly revealed that faster remission time, surgical intervention and treatment with SMA are linked to improved survival outcomes.

目的:本研究旨在了解肢端肥大症缓解时间对肢端肥大症患者生存期的影响:本研究旨在了解肢端肥大症缓解时间对肢端肥大症患者生存期的影响:这项横断面研究使用了英国肢端肥大症登记处的数据。我们认为,在确诊肢端肥大症后,生长激素控制在≤2 μg/L时,肢端肥大症病情缓解。我们使用加速失败时间模型来评估缓解时间对肢端肥大症患者生存率的影响:研究对象包括3569名肢端肥大症患者,确诊年龄中位数为47.3(36.5-57.8)岁,女性占48%,白人占多数(61%)。肢端肥大症首次缓解的人数为 2472 人,首次缓解的中位时间为 1.92(0.70-6.58)年。研究发现,肢端肥大症的首次缓解时间对患者的生存率有显著影响(p 结论:肢端肥大症的首次缓解时间对患者的生存率有显著影响:总之,这项针对肢端肥大症患者的人群研究显示,加快缓解时间、手术干预和使用 SMA 治疗与改善生存结果有关。
{"title":"Time to first remission and survival in patients with acromegaly: Evidence from the UK Acromegaly Register Study (UKAR)","authors":"Harshal Deshmukh,&nbsp;Emmanuel Ssemmondo,&nbsp;Kazeem Adeleke,&nbsp;Shiva Mongolu,&nbsp;Mo Aye,&nbsp;Steve Orme,&nbsp;Daniel Flanagan,&nbsp;Prakash Abraham,&nbsp;Claire Higham,&nbsp;Thozhukat Sathyapalan,&nbsp;UK Acromegaly Register Study (UKAR) Group","doi":"10.1111/cen.15112","DOIUrl":"10.1111/cen.15112","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to understand the effect of time to remission of acromegaly on survival in people living with acromegaly.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Design, Patients and Measurement</h3>\u0000 \u0000 <p>This cross-sectional study used data from the UK Acromegaly Register. We considered remission of acromegaly growth hormone controlled at ≤2 μg/L following the diagnosis of acromegaly. We used the accelerated failure time model to assess the effect of time to remission on survival in acromegaly.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study population comprises 3569 individuals with acromegaly, with a median age of diagnosis of 47.3 (36.5–57.8) years, 48% females and a majority white population (61%). The number of individuals with the first remission of acromegaly was 2472, and the median time to first remission was 1.92 (0.70–6.58) years. In this study, time to first remission in acromegaly was found to have a significant effect on survival (<i>p</i> &lt; .001); for every 1-year increase in time to first remission, there was a median 1% reduction in survival in acromegaly. In an analysis adjusted for covariates, the survival rate was 52% higher (<i>p</i> &lt; .001) in those who underwent surgery as compared to those who did not have surgery, 18% higher (<i>p</i> = .01) in those who received treatment with somatostatin analogues (SMA) as compared to those with dopamine agonists and 21% lower (<i>p</i> &lt; .001) in those who received conventional radiotherapy as compared to those who did not receive radiotherapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>In conclusion, this population-based study conducted in patients with acromegaly revealed that faster remission time, surgical intervention and treatment with SMA are linked to improved survival outcomes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141619474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical utility of untimed spot urine sampling in measuring calcium creatinine clearance in the diagnostic work-up of PTH-dependent hypercalcaemia 在 PTH 依赖性高钙血症的诊断工作中,非定时定点尿液采样在测量钙肌酐清除率方面的临床实用性。
IF 3 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-14 DOI: 10.1111/cen.15116
Ella Sharma, Chris Boot, Jason Ramsingh, Peter Truran, Richard Bliss, Andy James, Yaasir Mamoojee
{"title":"Clinical utility of untimed spot urine sampling in measuring calcium creatinine clearance in the diagnostic work-up of PTH-dependent hypercalcaemia","authors":"Ella Sharma,&nbsp;Chris Boot,&nbsp;Jason Ramsingh,&nbsp;Peter Truran,&nbsp;Richard Bliss,&nbsp;Andy James,&nbsp;Yaasir Mamoojee","doi":"10.1111/cen.15116","DOIUrl":"10.1111/cen.15116","url":null,"abstract":"","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enzyme replacement therapy for hypophosphatasia-The current paradigm. 低磷酸盐症的酶替代疗法--当前的范例。
IF 3 3区 医学 Q2 ENDOCRINOLOGY & METABOLISM Pub Date : 2024-07-14 DOI: 10.1111/cen.15063
Aaron Schindeler, Karissa Ludwig, Craig F Munns

Hypophosphatasia (HPP) is a rare, inherited, and systemic disorder characterized by impaired skeletal mineralization and low tissue nonspecific serum alkaline phosphatase (TNSALP) activity. It is caused by either autosomal recessive or dominant-negative mutations in the gene that encodes TNSALP. The phenotype of HPP is very broad including abnormal bone mineralization, disturbances of calcium and phosphate metabolism, pain, recurrent fracture, short stature, respiratory impairment, developmental delay, tooth loss, seizures, and premature death. Other than supportive care, there has been no disease-specific treatment available for those with HPP. Asfotase alfa is a fully humanized, recombinant enzyme replacement therapy for the management of HPP. It is available in several countries for the treatment of the more severe forms of HPP, namely perinatal and infantile HPP. This review will summarize the preclinical data on asfotase alfa and highlight the data from clinical trials and case reports. These data show the transformative nature of asfotase alfa when administered as part of an interdisciplinary treatment model.

低磷酸盐血症(HPP)是一种罕见的遗传性全身性疾病,其特征是骨骼矿化受损和组织非特异性血清碱性磷酸酶(TNSALP)活性低下。它是由编码 TNSALP 的基因发生常染色体隐性或显性阴性突变引起的。HPP 的表型非常广泛,包括骨矿化异常、钙磷代谢紊乱、疼痛、反复骨折、身材矮小、呼吸障碍、发育迟缓、牙齿脱落、癫痫发作和过早死亡。除了支持性护理外,目前还没有针对 HPP 患者的特定疾病治疗方法。Asfotase alfa 是一种用于治疗 HPP 的全人源化重组酶替代疗法。它已在多个国家上市,用于治疗较为严重的 HPP,即围产期和婴儿期 HPP。本综述将总结阿斯福通α的临床前数据,并重点介绍临床试验数据和病例报告。这些数据表明,在作为跨学科治疗模式的一部分进行治疗时,asfotase alfa 具有变革性。
{"title":"Enzyme replacement therapy for hypophosphatasia-The current paradigm.","authors":"Aaron Schindeler, Karissa Ludwig, Craig F Munns","doi":"10.1111/cen.15063","DOIUrl":"https://doi.org/10.1111/cen.15063","url":null,"abstract":"<p><p>Hypophosphatasia (HPP) is a rare, inherited, and systemic disorder characterized by impaired skeletal mineralization and low tissue nonspecific serum alkaline phosphatase (TNSALP) activity. It is caused by either autosomal recessive or dominant-negative mutations in the gene that encodes TNSALP. The phenotype of HPP is very broad including abnormal bone mineralization, disturbances of calcium and phosphate metabolism, pain, recurrent fracture, short stature, respiratory impairment, developmental delay, tooth loss, seizures, and premature death. Other than supportive care, there has been no disease-specific treatment available for those with HPP. Asfotase alfa is a fully humanized, recombinant enzyme replacement therapy for the management of HPP. It is available in several countries for the treatment of the more severe forms of HPP, namely perinatal and infantile HPP. This review will summarize the preclinical data on asfotase alfa and highlight the data from clinical trials and case reports. These data show the transformative nature of asfotase alfa when administered as part of an interdisciplinary treatment model.</p>","PeriodicalId":10346,"journal":{"name":"Clinical Endocrinology","volume":null,"pages":null},"PeriodicalIF":3.0,"publicationDate":"2024-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141615998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical Endocrinology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1